Chugai Unveils LUNSUMIO: A Breakthrough in Lymphoma Treatment

Chugai Pharmaceutical has officially launched LUNSUMIO® (mosunetuzumab) in Japan, bringing new hope to patients with relapsed or refractory follicular lymphoma who have undergone at least two prior treatments. This innovative bispecific antibody, approved by Japan’s Ministry of Health, Labour and Welfare in December 2024, is now listed on the national health insurance reimbursement price list. Designed to provide durable remission with a predefined treatment duration, LUNSUMIO offers a much-needed alternative for patients facing recurring lymphoma.

Chugai’s President and CEO, Dr. Osamu Okuda, emphasized the significance of this milestone, highlighting LUNSUMIO’s potential to ease the treatment burden on patients and their families. The approval is backed by promising data from the Japanese FLMOON-1 study and a global Phase I/II trial led by Roche, both demonstrating the drug’s efficacy as a monotherapy. With four-year follow-up data presented at ASH 2024, LUNSUMIO is poised to reshape the treatment landscape for follicular lymphoma, offering renewed hope for patients battling this challenging disease.